Further evidence for vitamin E's protection against Alzheimer's

- Last updated on GMT

Related tags: Antioxidant, Alzheimer's disease

Vitamin E may help prevent Alzheimer's disease, suggests new
research that provides insights into how the disease damages brain
cells.

UK researcher Allan Butterfield, based at the University of Kentucky in the US, studied amyloid beta peptide, a compound known to contribute to the senile plaques seen in the brains of Alzheimer's patients and thought by many to be responsible for the damage.

Writing in the October issue of the Journal of Alzheimer's Disease​ (vol 6, issue 5, pp515-25), Butterfield reports that in the animal form of the peptide, the introduction of the antioxidant vitamin E slowed the destruction of brain cells.

The research also demonstrates that both the amyloid beta peptide in the animal model and the same compound in humans both cause loss of connections between neurons and decreased cell viability as well as other damage associated with Alzheimer's.

"Beta(1-42) Rat [the animal form] was found to cause a significant increase in both protein oxidation and lipid peroxidation, similar to Abeta(1-42), both of which were inhibited by the lipid-soluble, chain breaking antioxidant vitamin E, suggesting that reactive oxygen species play a role in the Abeta-mediated toxicity,"​ write the researchers.

Previous studies have shown that antioxidant vitamins may protect the brain against damage caused by free radicals and other reactive oxygen species produced during basic cellular metabolism. Neurons are especially sensitive to damage caused by free radicals, which is believed to be partially responsible for the development of Alzheimer's disease.

A study by John Hopkins researchers earlier this year​ found that people who took supplements of vitamin E in combination with vitamin C were less likely to develop the disease, however there was no evidence of benefit from multivitamins, or the vitamin alone.

There are nearly 18 million people with dementia in the world and the most common cause of this dementia is Alzheimer's disease. By 2025 this figure will rise to 34 million, with 71 per cent of these likely to live in developing countries.

The new study also proposes new mechanisms of action of the human amyloid beta peptide, as it identifies methionine in the peptide as a key contributor to Alzheimer's disease. A previous theory held that it was the copper binding sites in the human peptide that contributed to Alzheimer's.

The animal form of the peptide, which does not have the copper binding sites, still causes damage. Butterfield says this indicates the damage to neurons caused by the human peptide in an Alzheimer's disease patient is related to the peptide's methionine residue.

Related news

Show more

Related products

show more

WHERE THE WORLD IS GOING NEXT FOR VITAMIN D

WHERE THE WORLD IS GOING NEXT FOR VITAMIN D

PLT Health Solutions | 22-Jun-2022 | Product Brochure

Earthlight® Whole Food Vitamin D is a clean label ingredient that can help you create cutting-edge fortified foods and supplements. Low use levels mean...

Whitepaper: Optimizing immunity with vitamin D

Whitepaper: Optimizing immunity with vitamin D

DSM Nutritional Products | 16-Jun-2022 | Technical / White Paper

With vitamin D science evolving rapidly since the COVID-19 pandemic, our new whitepaper breaks down the latest research on the role of vitamin D in supporting...

Stronger Bones Begin with MenaQ7® Vitamin K2

Stronger Bones Begin with MenaQ7® Vitamin K2

Gnosis by Lesaffre | 06-Jun-2022 | Infographic

By activating the K-dependent protein Osteocalcin, Vitamin K2 as MK-7 enables the body to properly utilize calcium, binding it to the bone matrix.

A proactive approach to wellness.

A proactive approach to wellness.

ADM | 31-May-2022 | Case Study

Gain valuable insights into the attitudes, behaviors and priorities of the supplement consumer of the future with ADM’s detailed new case study. Inside,...

Related suppliers

Follow us

Products

View more

Webinars